DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Le Burel S, Champiat S, Mateus C. et al.
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Eur J Cancer 2017;
82: 34-44
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.